Hemodynamic Consequences of Laparoscopy for Patients on Mechanical Circulatory Support

Heidi Reich 1,2, Danny Ramzy 1, Alagappan Annamalai 2, Lawrence Czer 1, Fardad Esmailian 1, Jaime Moriguchi 1, Kai Ihnken 1, Taizoon Yusufali 3, Nicola D'Attellis 3 and Francisco Arabia 1

1Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, USA
2Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, USA
3Department of Anesthesiology, Cedars-Sinai Medical Center, Los Angeles, USA

Keywords: Circulatory assist devices (LVAD, RVAD, BVAD, TAH); Hemodynamics; Minimally invasive surgery (incl port access, minithoracotomy); Outcomes (incl mortality, morbidity, survival, etc.)

Abstract

Background: Technologic advances and superior survival with mechanical circulatory support (MCS) led to an expanding population that develops intra-abdominal conditions requiring intervention. Whether laparoscopy can be performed without detrimental effects on hemodynamics and device function is not well-described.

Methods: Effects of laparoscopy performed on MCS were retrospectively assessed. Intraoperative hemodynamics and device function were compared to the same time interval 24h prior to surgery using intrapatient paired t-tests. Outcomes included survival, transfusion, thromboembolic events, and infection.

Results: Twelve patients with ventricular assist devices or total artificial hearts underwent laparoscopy from 2012-2014. Median follow-up was 116 days. Operations included cholecystectomy, adjusting device speed, or pharmacologic support. There were no operative mortalities. 30-day survival and survival to discharge were 75% and 50%. Despite antiplatelet therapy and preoperative INR of 2.2 ± 0.9, there were no re-operations for bleeding and 50% did not require transfusion. Two patients with recent cardiac surgery had thromboembolic events: 1 stroke, 1 device thrombus. None had postoperative bacteremia or drive-line infection.

Conclusions: Laparoscopy can be performed on mechanical circulatory support with low morbidity and mortality and minimal perturbations in hemodynamics and device function.

Introduction

Over the last 15 years, advances in mechanical circulatory support (MCS) have dramatically changed mortality, morbidity, and quality of life for patients with advanced heart failure. Over 5.8 million U.S. adults have heart failure [1], which includes an estimated 250-500,000 with end-stage heart failure refractory to medical management [2]. Current indications for durable MCS include acute cardiogenic shock with ventricular function that is unrecoverable or unlikely to recover without a long-term device support, inability to maintain normal hemodynamics and vital organ function with temporary devices or inability to wean from temporary devices or inotropic support, capacity for meaningful recovery of end-organ function and quality of life, and absence of irreversible end-organ damage [3]. In addition, patients with inotrope-dependence or patients with heart failure and high predicted one-year mortality should be evaluated for MCS [3].
In the United States alone, over 2,500 durable mechanical circulatory support devices, which include left and/or right ventricular assist devices (LVADs, RVADs, BiVADs) and total artificial hearts (TAHs), are implanted annually [4]. The increasing rate of device implantations reflects improved understanding of the benefit devices offer patients with advanced heart failure that began with the REMATCH study [5]. One and two year survival with continuous flow LVADs are now 80% and 70% and over 40% of devices are placed as destination therapy [4] for patients who are ineligible for heart transplantation, often because of advanced age or comorbidities.

As the rate of device implantation and duration of support increase, there is an expanding population of MCS patients at risk for treatment of intra-abdominal pathology. As improvements in non-cardiac surgery have been favorable with equivalent one-year survival when compared to LVAD patients not requiring non-cardiac surgery are multifactorial, but are largely attributed to the combined influences of peritoneal absorption of carbon dioxide, elevated intraabdominal pressures, and patient positioning. The effects on various organ systems were established in healthy patients not on mechanical circulatory support devices. Concerns that patients with advanced heart disease may be more susceptible to these changes and less able to mount appropriate compensatory responses remain are counterbalanced by a small, but growing, number of reports that laparoscopy can be safely performed in patients with mechanical circulatory support devices.

As of 2012, laparoscopic cholecystectomy was standard of care for patients on mechanical circulatory support. The use of laparoscopic surgery in patients with persistent hypertension, impaired left ventricular function, and mechanical circulatory support devices is an uninvestigated. Whether pneumoperitoneum has similar effects on the physiology of patients on MCS remains uninvestigated.

To explore our hypothesis that laparoscopy can be performed safely on MCS patients, we reviewed our experience with a focus on intraoperative hemodynamics, device parameters, and complications such as death, bleeding, thrombosis, or infection.

Methods

Study design

All patients with left ventricular assist devices, biventricular assist devices, or total artificial hearts undergoing laparoscopic operations performed by one surgeon at Cedars-Sinai Medical Center from August 2012 to April 2014 were included for retrospective analysis to characterize the effects of laparoscopy on MCS. MCS patients undergoing planned laparotomy were excluded. To account for inter-patient variation in preoperative clinical status, each patient served as his/her own control: intraoperative hemodynamics and device function were compared to the same time interval 24 hours prior to surgery using intra-patient paired t-tests. This study was reviewed and approved by the Cedars-Sinai Institutional Review Board.

Operative approach and anesthetic technique

All operations were performed with cardiac anesthesia and perfusion teams. Anticoagulation (Warfarin or Heparin) and antiplatelet (Aspirin) therapies were not routinely held; anticoagulation was reversed with fresh frozen plasma selectively. All patients underwent general anesthesia with endotracheal intubation and were positioned supine with reverse Trendelenberg. All patients underwent arterial line placement; central venous and pulmonary artery catheters were used selectively. Intravenous fluids were minimized, with 3/12 patients receiving no crystalloid or colloid and 4/12 receiving less than 500 cc (mean volume of fluids administered: 550 ± 541 cc). Drivelines were prepped and draped within the operative field. Preoperative antibiotics were administered prior to skin incision. The most frequent antibiotic selections were Piperacillin-Tazobactam or Cefazolin for cholecystectomy or gastroscopy, respectively. Carbon dioxide pneumoperitoneum was delivered via a Veress needle to achieve pressures of 12-15 mmHg. The position of trocar sites were modified based on the location of drivelines (Figure 2). Fascia for all trocar sites ≥ 10 mm was closed and skin was closed with absorbable monofilament suture.
Figure 2: Standard trocar locations for a laparoscopic cholecystectomy include supraumbilical, subxiphoid, medial right subcostal, and lateral subcostal sites (A) and modified trocar placement relative to driveline locations for patients with left ventricular assist device (B), biventricular assist device (C), and total artificial hearts (D) undergoing laparoscopic cholecystectomy. Initial trocar placement was via supraumbilical for LVAD and TAH and infraumbilical for BiVAD. The subxiphoid trocar site was placed more caudally to avoid LVAD and BiVAD drivelines and more caudally and more rightward to avoid TAH drivelines. Avoidance of the BiVAD drivelines also required shifting all trocar sites caudally.

Outcomes

Hemodynamic and device parameter data recorded by anesthesiologists, perfusion technologists, and cardiac surgery intensive care nurses were collected. Postoperative outcomes and major adverse events, including patient survival, reoperation for bleeding, need for transfusion, thromboembolic events or infections, were also analyzed. Thromboembolic events included stroke, defined as the presence of any neurologic deficit and/or CT findings consistent with intracranial hemorrhage or ischemic stroke, and device-associated thrombus identified by echocardiography. Infections were defined as clinically-suspected or culture-proven infection requiring antibiotic treatment or opening of wound and were categorized as bacteremia, urinary tract infection, pneumonia, abdominal surgical site infection, or drive line infection.

Statistical Analysis

Continuous variables are expressed as the mean ± standard deviation or median (range) and categorical variables are presented as count (%). Differences between preoperative and intraoperative parameters were assessed by paired student’s t-tests with significance defined as two-tailed p-values<0.05. The statistical analysis was performed using GraphPad Prism 5 for Windows (GraphPad Software, San Diego CA).

Results

Twelve patients with ventricular assist devices or total artificial hearts underwent laparoscopy. Median follow-up was 116 (3-371) days. The types of device and operations performed are summarized in Table 1 and preoperative patient characteristics in Table 2. Median procedure time was 2 hours 23 minutes (53 minutes–4 hours 12 minutes). There was a single conversion to open.

<table>
<thead>
<tr>
<th>Device</th>
<th>Operation</th>
<th>N</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVAD</td>
<td>laparoscopic cholecystectomy</td>
<td>4</td>
<td>acute cholecystitis (3), gallstone pancreatitis</td>
</tr>
<tr>
<td>LVAD</td>
<td>laparoscopic gastrojejunostomy</td>
<td>1</td>
<td>malnutrition</td>
</tr>
<tr>
<td>BiVAD</td>
<td>diagnostic laparoscopy</td>
<td>1</td>
<td>possible acalculous cholecystitis</td>
</tr>
<tr>
<td>BiVAD</td>
<td>laparoscopic gastrostomy</td>
<td>1</td>
<td>dysphagia</td>
</tr>
<tr>
<td>TAH</td>
<td>laparoscopic cholecystectomy</td>
<td>3</td>
<td>acute cholecystitis (2), biliary dyskinesia</td>
</tr>
<tr>
<td>TAH</td>
<td>laparoscopic gastrojejunostomy</td>
<td>1</td>
<td>failure to thrive</td>
</tr>
<tr>
<td>TAH</td>
<td>diagnostic laparoscopy</td>
<td>1</td>
<td>sepsis, possible intestinal ischemia</td>
</tr>
</tbody>
</table>

LVAD, Left-Ventricular Assist Device; Bivad, Biventricular Assist Device; TAH, Total Artificial Heart

Table 1: Mechanical circulatory support device and operation performed.

At baseline, average heart rate (HR) was 83.2 ± 18.04 bpm, mean arterial pressure (MAP) was 77.02 ± 10.89 mmHg, inotrope requirement was 2.5 ± 5.00 mcg/min, and vasopressor requirement was 0.01 ± 0.02 U/min. There were no differences between preoperative and intraoperative HR, MAP, or inotrope or vasopressor requirements (Table 3, p-values 0.23-0.45). Device fill volume, flow, rate, and power were unchanged (p-values 0.20-0.93), while pulsatility index decreased by 0.2, 95% CI [.03, 0.36], with laparoscopy (Table 3, p=0.03). All intraoperative fluctuations in hemodynamics and device function improved with reduction of pneumoperitoneum, adjusting device speed, or pharmacologic support. There were no device power interruptions due to electrocautery interference. Of 5 patients on inotropic or pressor support prior to surgery, 1 (20%) required a brief increase in support (epinephrine raised from 1.5 to 2.5 mcg/min), 1 (20%) tolerated intraoperative reduction of support, and 3 (60%) were stable without adjustments of pharmacologic support. 2 of seven patients not on inotropes or pressors were given intraoperative inotropes.

<table>
<thead>
<tr>
<th>Age</th>
<th>63.5 (35-81) years</th>
</tr>
</thead>
<tbody>
<tr>
<td>M:F</td>
<td>7:5</td>
</tr>
<tr>
<td>BMI</td>
<td>23.2 (18.8-39.9) kg/m2</td>
</tr>
<tr>
<td>ICM:NICM</td>
<td>7.5</td>
</tr>
<tr>
<td>Intermacs profile 1 or 2</td>
<td>7 (58%)</td>
</tr>
<tr>
<td>Device Strategy: BTT</td>
<td>8 (75%)</td>
</tr>
<tr>
<td>Duration of MCS</td>
<td>50 (1-863) days</td>
</tr>
</tbody>
</table>

Table 2: Preoperative patient characteristics and intraoperative parameters.
Mechanical Ventilation 5 (42%)
Inotropes, Vasopressors 5 (42%)
Hemodialysis 3 (25%)
Prior abdominopelvic surgery 5 (42%)
INR 2.2±0.9
Hematocrit 25.8±3.57 mg/dL
Platelet Count 261(166-470) thousand
Aspirin 11 (92%)
Red blood cell transfusion 2 (20%)
Fresh frozen plasma transfusion 2 (20%)
Platelet transfusion 0

Table 2: Preoperative patient characteristics

There were no operative mortalities. 30-day survival and survival to discharge were 75% and 50%. Despite antiplatelet therapy and preoperative INR of 2.2 ± 0.9, there were no re-operations for bleeding and 50% did not require transfusion 48 hours before, during, or after surgery. Two patients with recent cardiac surgery had thromboembolic events: 1 stroke, 1 device thrombus. No patient had postoperative bacteremia, urinary tract infection, pneumonia, or drive line infection. Two patients had superficial surgical site infections: one at the umbilical trocar site that resolved after opening of the incision and one at the gastrostomy tube site that resolved with local wound care.

HD Parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th># pairs</th>
<th>Mean Difference (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR (bpm)</td>
<td>7</td>
<td>-5.71 [-23.08, 11.65]</td>
<td>0.45</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>12</td>
<td>-4.47 [-12.28, 3.34]</td>
<td>0.23</td>
</tr>
<tr>
<td>Inotrope (mcg/min, mcg/kg/min)</td>
<td>12</td>
<td>0.92 [-1.31, 3.14]</td>
<td>0.38</td>
</tr>
<tr>
<td>Pressor (units/min)</td>
<td>12</td>
<td>0.00 [-0.00, 0.00]</td>
<td>0.34</td>
</tr>
</tbody>
</table>

Device Parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th># pairs</th>
<th>Mean Difference (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Device Rate (rpm, bpm)</td>
<td>9</td>
<td>0.85 [-0.63, 2.33]</td>
<td>0.22</td>
</tr>
<tr>
<td>L Fill Volume (mL)</td>
<td>6</td>
<td>-0.49 [-7.96, 6.98]</td>
<td>0.87</td>
</tr>
<tr>
<td>R Fill Volume (mL)</td>
<td>6</td>
<td>0.21 [-5.77, 6.18]</td>
<td>0.93</td>
</tr>
<tr>
<td>L Flow (lpm)</td>
<td>12</td>
<td>0.24 [-0.15, 0.64]</td>
<td>0.2</td>
</tr>
<tr>
<td>R Flow (lpm)</td>
<td>6</td>
<td>0.10 [-0.38, 0.58]</td>
<td>0.61</td>
</tr>
<tr>
<td>Pulsatility Index</td>
<td>4</td>
<td>0.20 [0.33, 0.36]</td>
<td>0.03</td>
</tr>
<tr>
<td>Power (Watts)</td>
<td>5</td>
<td>1.39 [-1.73, 4.52]</td>
<td>0.28</td>
</tr>
</tbody>
</table>

Mean difference>0 corresponds to a decrease in the parameter with laparoscopy

Bpm: Beats Per Minute; Mmhg: Millimeters of Mercury; Mcg/Min: Micrograms per Minute; Kg: Kilograms; Rpm: Revolutions per Minute; Ml: Milliliters; Lpm: Liters per Minute

Table 3: Difference between baseline and intraoperative hemodynamics and device parameters

Discussion

In the largest study to date describing the experience of laparoscopy performed on MCS patients, we found that laparoscopy was both feasible and safe to perform in MCS patients. Previous reports of applications of laparoscopy to MCS patients were similarly encouraging, but limited to single patient case reports and very small case series (Table 4). Although prior reports have stated that laparoscopy was well-tolerated, our study is the first to report and quantitatively analyze whether hemodynamics and device parameters change with laparoscopy. Our sample represents a diverse cohort of MCS patients with multiple types of devices and inclusion of patients who were clinically stable or unstable prior to surgery.

Table 4: Reports of laparoscopy performed in patients with mechanical circulatory support

We identified a small but statistically significant decrease in the pulsatility index associated with pneumoperitoneum. The pulsatility index is calculated as \( \frac{\text{flow}_{\text{max}} - \text{flow}_{\text{min}}}{\text{flow}_{\text{mean}}} \times 10 \) and ranges from 1-10. It represents the magnitude of the flow pulse generated by an LVAD through each cardiac cycle and reflects the balance between ventricular contractility and the degree of unloading. The pulsatility index is dependent on LVAD speed and preload. The magnitude of the reduction in pulsatility index we observed, 0.2, was less than our prospectively assigned threshold for clinical relevance of 0.5. Although the reduction was small in magnitude, this change was consistent with the effects of pneumoperitoneum described in non-MCS patients, which include preload reduction. If the pulsatility index were to decrease during laparoscopy in association with hypotension or
reduced flow, appropriate responses include looking for bleeding, reducing insufflation pressures, leveling the bed if in reverse trendelenberg, giving volume, and obtaining an echocardiogram. In an otherwise hemodynamically stable patient with a decrease in pulsatility index, transesophageal echocardiography is a useful adjunct to assess for evidence of hypovolemia or right ventricular depression to further guide management.

We believe that a well-coordinated team approach to perioperative care is an important element in ensuring the best outcomes for MCS patients in need of abdominal operations. Our team approach included close coordination of perioperative care with the MCS team, performing all operations with the assistance of cardiac anesthesiologists in a cardiac operating room with a perfusionist present and the cardiac surgeon immediately available if questions about device function or driveline positions arose. Modifications in traditional laparoscopic port placement are sometimes necessary to avoid the drivelines.

Decisions concerning perioperative management of anticoagulation and antiplatelet therapy should be based on the input of the MCS team and the operating surgeon. The 2013 International Society for Heart and Lung Transplantation guidelines for MCS patient requiring non-cardiac surgery recommend continuation of anticoagulation and antiplatelet therapies if bleeding risk is low, holding with or without a heparin bridge if warranted by risk of bleeding, reversal of Coumadin with fresh frozen plasma or vitamin K if needed for emergency procedures, and resuming anticoagulation and antiplatelet therapy when risk of surgical bleeding is acceptable.3 Historically, coagulopathy was considered a contraindication to laparoscopy, but this has largely fallen out of favor as meticulous surgical technique and advanced instruments have facilitated the safe application of laparoscopy patients with cirrhosis and hematologic disorders.21 Previous studies, in which open approaches were more frequent, described bleeding as the most common complication [8,9]. While the risk of bleeding could be a major limitation to performing laparoscopy on MCS, we did not find this to be a problem. In our series, we found that meticulous attention to hemostasis facilitated avoidance of withholding or reversing anticoagulation or antiplatelet therapy without leading to any reoperations for bleeding. Because MCS patients are at elevated risk of thromboembolic events, withholding or reversing anticoagulation or antiplatelet therapies if bleeding risk is low, holding with or without a heparin bridge if warranted by risk of bleeding, reversal of Coumadin with fresh frozen plasma or vitamin K if needed for emergency procedures, and resuming anticoagulation and antiplatelet therapy when risk of surgical bleeding is acceptable.

Conclusion

Laparoscopy can be performed on mechanical circulatory support with low morbidity and mortality and minimal perturbations in hemodynamics and device function. This is the first study to quantify the effects of pneumoperitoneum for patients on mechanical circulatory support.

References